Scientific Activities of the California Pacific Medical Center Research Institute

2009 Compendium of Peer-Reviewed Publications
Scientists at the California Pacific Medical Center Research Institute are involved in a variety of laboratory and clinical research projects. This report includes manuscripts published in the peer-reviewed literature in 2009, listed in alphabetical order by Principal Investigator (PI). We appreciate the contributions of many other scientists (including post-doctoral fellows and technicians) in the Research Institute.

**Ari Baron, MD (abar@phoamd.com)**


**Eric Beattie, PhD (beattie@cpmcri.org)**


**Kenneth Binmoeller, MD (binmoek@sutterhealth.org)**


**Michael Borah, MD (borahm@sutterhealth.org)**

Warren Browner, MD, MPH (warren@cpmcri.org)


See also Steve Cummings.

Natalie Bzowej, MD (bzowejn@sutterhealth.org)


Peggy Cawthon, PhD (pcawthon@sfcc-cpmc.net)


See also Steve Cummings and Katie Stone.
Charles Cobbs, MD (charles.cobbs@gmail.com)


Steve Cummings, MD (scummings@sfc cpmc.net)


See also Peggy Cawthon and Katie Stone

Shanaz Dairkee, PhD (dairkees@cpmcri.org)


Tim Davern, MD (davernt@sutterhealth.org)


2009 Compendium


Robert Debs, MD (debs@cpmcri.org)

See Mohammed Kashani-Sabet.

Pierre Desprez, PhD (pydesprez@cpmcri.org)


Catherine Frenette, MD (frenetc@sutterhealth.org)

See Robert Gish.

Anne Fung, MD (annefungmd@yahoo.com)


Gantt Galloway, PharmD (gantt@cpmcri.org)


See also John Mendelson.

**Robert Gish, MD** (gishr@sutterhealth.org)

Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. *J Viral Hepat*. 2009 Nov;16(11):784-9.


**Frenette CT, Gish RG**. To "be" or not to "be": that is the question. *Am J Gastroenterol*. 2009 Aug;104(8):1948-52.

**Shelley Gordon, MD** (gordons@sutterhealth.org)

Dieter Gruenert, PhD (dieter@cpmcri.org)


Steven Hao, MD (haos@sutterhealth.org)


Peter Y. Hui, MD (phui@cpemg.com)


Giuseppe Inesi, MD (inesig@cpmcri.org)


Mohammed Kashani-Sabet (kashanm@cpmcrl.org)


See also David Minor.
Jonathan Katz, MD (katzjs@cpmcri.org)


See also Robert Miller and Susan Woolley-Levine

Steven Katznelson, MD


Kevin Knopf, MD (kknopf@phoamd.com)


Sandra Luna-Fineman, MD (lunafis@sutterhealth.org)


Stanley P. L. Leong, MD, FACS (leongsx@cpmcri.org)


See also Mohammed Kashani-Sabet

**Catherine Madison, M.D (madisoca@cpmeri.org)**


**John Mendelson, MD (mendelje@cpmeri.org)**


**Raphael Merriman, MD (merrimannr@sutterhealth.org)**


**Robert Miller, MD (millerrx@cpmeri.org)**


See also Jonathan Katz.

**David Minor, MD (minord@sutterhealth.org)**


Smylie M, Francis S, Neyns B, Maio M, **Minor D**, et al: Ipilimumab at 10mg/kg improves disease control in patients with M1c-stage melanoma regardless of baseline lactate dehydrogenase (LDH) levels. 2009. *J Clin Oncol.* 27: 471s


**Minor DR.** Risk of venous thromboembolism with bevacizumab in cancer patients. *Jama.* 2009 Apr 8;301(14):1434; author reply 5-6.

Dan Moore, PhD (mooredx@cpmcri.org)

See Robert Miller, David Minor, and Garret Yount

**John Muschler, PhD (muschler@cpmcri.org)**


**V. Ram Peddi, M.D. (peddir@sutterhealth.org)**


**Michael Rowbotham, MD (rowbotm@cpmcri.org)**


Anthony Quiros, MD (quirosj@sutterhealth.org)


Richard Shaw, PhD (shawr@sutterhealth.org)


Katie Stone, PhD (kstone@sfcc-cpmc.net)


See also Steve Cummings

Gregory Tranah, PhD (grtranah@sfcc-cpmc.net)


Cassi Vieten, PhD (vietenc@cpmcri.org)


Esther Wei, ScD (weie@cpmcri.org)


Susan Woolley-Levine, PhD (woolles@sutterhealth.org)


See also Robert Miller

Lowell Young, MD (younglx@cpmcri.org)


Garret Yount, PhD (yountg@cpmcri.org)